HPE Managing CINV pocket guide 2019 | Page 47

Direct non-healthcare cost Productivity losses Informal care Work days lost due to CINV Transportation to hospital for CINV treatment Lost income resource utilisation for patients experiencing any CINV episode during the six-month period preceding the survey. Furthermore, the cost associated with severe CINV episode management was estimated by adopting the National Health Service’s perspective. Mean costs per patient for treatment of a single severe CINV episode were €389, €750 and €1017, respectively, in these countries. 13 These data underline that a complete control of CINV is a reasonable approach for prophylaxis from the economic point of view. of the direct healthcare costs incurred by healthcare systems and patients and it represents a major cost component in CINV-related studies. Pharmacoeconomic studies normally compare two or more treatment alternatives or, in some cases, they aim to assess costs and consequences of one single therapy. Another dimension that helps frame the analysis is whether both outcomes and costs or only costs are considered. In the latter case, the analysis is considered a partial evaluation. This type of analysis can take the form of a cost-description or cost- outcome description (that is, there is no comparator), or of a cost analysis (that is, two alternative Pharmacoeconomics of CINV Pharmaceutical treatment is one hospitalpharmacyeurope.com | 2019 | 47